Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion type Assertion NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_head.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion description "[To evaluate the effects of dexloxiglumide, a CCK-1 receptor antagonist, on gastrointestinal transit (GIT) and symptoms in patients with constipation-predominant IBS (C-IBS); and to explore the influence of CCK-1 receptor polymorphisms on gut transit and the pharmacodynamic response to therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_provenance.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion evidence source_evidence_literature NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_provenance.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion SIO_000772 15743365 NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_provenance.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion wasDerivedFrom befree-20140225 NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_provenance.
- NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_assertion wasGeneratedBy ECO_0000203 NP519225.RAwsvlZAJU8l6lXJEIvITKk4PdIDFO3f9ioB2Yh2bI-mk130_provenance.